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Objective: To test the effects of sequential exposure to FGF2, 9 and 18 on human Mesenchymal Stem Cells
(hMSC) differentiation during in vitro chondrogenesis.
Design: Control and FGF2-expanded hMSC were cultured in aggregates in the presence of rhFGF9,
rhFGF18 or rhFGFR3-speciﬁc signaling FGF variants, starting at different times during the chon-
droinductive program. Quantitative real time polymerase chain reaction (qRT-PCR) and immunocyto-
chemistry were performed at different stages. The aggregate cultures were switched to a hypertrophy-
inducing medium along with rhFGFs and neutralizing antibodies against FGFR1 and FGFR3. Histologi-
cal/immunohistochemical/biochemical analyses were performed.
Results: FGF2-exposed hMSC during expansion up-regulated Sox9 suggesting an early activation of the
chondrogenic machinery. FGF2, FGF9 and 18 modulated the expression proﬁle of FGFR1 and FGFR3 in
hMSC during expansion and chondrogenesis. In combination with transforming growth factor-beta (TGF-
b), FGF9 and FGF18 inhibited chondrogenesis when added at the beginning of the program (d7), while
exhibiting an anabolic effect when added later (d14), an effect mediated by FGFR3. Finally, FGFR3
signaling induced by either FGF9 or FGF18 delayed the appearance of spontaneous and induced
hypertrophy-related changes.
Conclusions: The stage of hMSC-dependent chondrogenesis at which the growth factors are added im-
pacts the progression of the differentiation program: increased cell proliferation and priming (FGF2);
stimulated early chondrogenic differentiation (TGF-b, FGF9/FGF18) by shifting the chondrogenic program
earlier; augmented extracellular matrix (ECM) production (FGF9/FGF18); and delayed terminal hyper-
trophy (FGF9/FGF18). Collectively, these factors could be used to optimize pre-implantation conditions of
hMSC when used to engineer cartilage grafts.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The expansion potential and the ability to differentiate into
chondrocytes of humanMesenchymal Stem Cells (hMSC) have been
studied and documented extensively. These cells constitute an: D. Correa, Department of
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ternational. Published by Elsevier Linteresting alternative to autologous chondrocytes to treat chon-
dral and osteochondral defects1e3. However, much work still needs
to be done before hMSC can be accepted as a front-line treatment,
mainly due to the difﬁculties associated with the control of a
deﬁnitive chondrocyte phenotype capable of fabricating stable
hyaline cartilage.
A salient feature of existing in vitro approaches to the expansion
and chondrogenic differentiation of hMSC is that they use one-step
stimulation, in the sense that a single culture medium is used to
expand the cells, and a single chondrogenic formulation is used to
drive the entire multi-step differentiation process. Yet, to date, true
hyaline articular cartilage has not been successfully engineered
using hMSC following these simple approaches, highlighting the
need for optimization of these formulations. For this reason, andtd. All rights reserved.
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re-thinking of these assumptions. The observations that serve as
ground for the new approach are: ﬁrst, the ﬁnding that hMSC can
be speciﬁcally primed for subsequent chondrogenic differentiation
and massive ECM formation by stimulating cells with FGF2 during
the expansion phase4,5; second, the recognition that marrow hMSC
likely have an intrinsic differentiation program, analogous to
endochondral bone formation and fracture healing, which drives
new chondrocytes to terminal hypertrophic differentiation and the
generation of a “transient” cartilaginous ECM with different
structure and function compared to hyaline native articular
cartilage6e9; and third, borrowing from developmental biology and
embryonic stem cell research, it is clear that a sequential exposure
to different bioactive molecules is required to drive differentiation
towards particular cellular phenotypes10,11.
The effects of FGF2 on hMSC have been extensively studied,
showing an enhancement in proliferation and chondrogenic po-
tential when applied during the expansion phase5. In contrast,
when applied during chondrogenic differentiation, it has a negative
effect on matrix deposition and differentiation12,13.
FGF18 has recently gained attention due to its demonstrated
anabolic effects on cartilage14. In mature articular chondrocytes, in
both in vitro and in vivo models of articular cartilage injury, FGF18
exhibits mitogenic activities in addition to increased ECM produc-
tion, thereby promoting cartilage repair15e17. These observations
have led to the design of clinical trials to study the use of intra-
articular injections of FGF18 as an alternative treatment for
different stages of knee Osteoarthritis (OA) and for acute cartilage
injuries (Merck Serono, Switzerland). On the other hand, much less
is known regarding the role of FGF9 during cartilage biology and
repair. FGF9 has similar receptor speciﬁcities as FGF-18 while
belonging to a different subfamily of FGF ligands. FGF9 is known to
signal from epithelium to mesenchyme inducing mesenchymal
proliferation, and to induce the production of other FGF family
members involved in sex determination and lung development18.
During skeletal development, FGF9 is expressed in the proximity of
developing skeletal elements (apical ectodermal ridge), affecting
skeletogenesis consequent to mesenchymal cell condensation.
FGF9/ mice exhibit rhizomelia, a condition characterized by
shortening of proximal skeletal elements19. In addition, FGF9 seems
to be able to redirect cranial development mesenchyme from an
intramembranous to an endochondral process20. Finally, during
in vitro hMSC chondrogenic differentiation, is has been shown that
FGF9 exerts a negative effect when present throughout the entire
differentiation program12. On the other hand, FGFR3 has been
demonstrated to have a positive impact on chondrogenic differ-
entiation as well as matrix deposition by differentiated chon-
drocytes (proanabolic effect), in sharp contrast with FGFR1-
dependent signaling, described as procatabolic and anti-
anabolic14,15,21e23. In fact, a resulting FGFR3:FGFR1 ratio is signiﬁ-
cantly reduced in OA and proposed as a potential target for
therapeutic modiﬁcation21. This signaling antagonism downstream
of both receptors, in addition to the known lack of full receptor
speciﬁcity of FGF ligands would suggest the use of FGFR3-speciﬁc
ligands in order to augment the positive response.
On the basis of the need of a re-thinking of the established as-
sumptions for in vitro chondrogenic differentiation of hMSC, we
now propose a new approach, one that “mimics” embryonic
development. In this approach we assume that the entire chon-
drogenic program is controlled by a combination of various growth
factors sequentially delivered, with each step individually modu-
lated, resulting in a cellular phenotype that generates a more
“permanent” hyaline-like cartilage ECM that could be implanted
in vivo to treat chondral and osteochondral defects. The experi-
ments reported here elucidate the effect of these FGF familymembers when used at different stages of the in vitro chondrogenic
differentiation program of hMSC.
Methods
Cell cultures
Cultures of hMSC were established as previously described24,25.
The marrow was collected using a procedure reviewed and
approved by the University Hospitals of Cleveland Institutional
Review Board; informed consent was obtained from all donors.
Cells were obtained from four healthy de-identiﬁed adult volunteer
donors, and expanded in either Dulbecco's Modiﬁed Eagle's Me-
dium-Low Glucose (DMEM-LG) þ Fetal Bovine Serum (FBS) 10%
(Control-expanded) or DMEM-LG þ FBS 10% þ 10 ng/ml FGF2
(FGF2-expanded) for 14 days. All results were calculated, compared
and shown using data obtained from all donors (six pellets per
condition) and run in triplicate. An intrinsic variability was seen
among absolute values obtained with the four donors, yet the data
is consistent among them.
Chondrogenic induction
Control and FGF2-expanded cells were cultured in aggregates4,5
with complete chondrogenic medium (DMEM-HG supplemented
with 1% ITS, 107 M dexamethasone, 1 mM sodium pyruvate,
120 mM ascorbic acid-2 phosphate, 100 mM non-essential amino
acids and 10 ng/ml transforming growth factor-beta 1 (TGF-b1)), in
the presence of 10 ng/ml rhFGF18, 10 ng/ml rhFGF9, 10 ng/ml
mutant ligands that exclusively signal through FGFR3 (FGF9v1 and
FGF18v3) and neutralizing antibodies against FGFR1 (0.1 mg/ml)
and FGFR3 (0.5 mg/ml) (Procore; Ness Ziona, Israel) starting at
different times of the chondroinductive program. FGF18v3 is a
truncated version of FGF18 lacking the amino-terminal 51 amino
acids of the ligand and having the ﬁrst methionine replacing
Glutamine 51. FGF9v1 is likewise a truncated version of FGF9
lacking the amino-terminal 37 amino acids of the ligand and having
tryptophane 144 substituted for Glycine. Histological/biochemical,
immunocytochemistry and Quantitative real time polymerase
chain reaction (qRT-PCR) analyses were performed at different time
points during the differentiation progression.
Antibody penetration to pellets
To conﬁrm the penetration and distribution of the FGFR
neutralizing antibodies inside the ECM-rich pellet, the anti-human
FGFR3 neutralizing antibody was added at different time points
during the aggregate culture (d0, d7, d14), and immunolocalized in
frozen sections at days 21 with an anti-mouse secondary antibody.
Hypertrophy delay
Aggregate cultures of FGF2-expanded cells were switched after
2 weeks to a hypertrophy-inducing medium (TGF-b withdrawal,
low dexamethasone,1 ng/ml triiodothyronine)6,7 for two additional
weeks, along with rhFGF18, rhFGF9, FGF18v3, FGF9v1, and the
FGFR1/FGFR3 neutralizing antibodies. Histological/biochemical
analyses and alkaline phosphatase (ALP) activity assessment
(Supplemental methods) as a marker of hypertrophy-induced
changes were then performed.
Histology/immunohistochemistry
Pellets were ﬁxed, parafﬁn-embedded, and sectioned. Adjacent
sections were stained with toluidine blue O to evaluate
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chemistry, pellet sections were deparafﬁnized/rehydrated followed
by antigen retrieval through incubationwith 10 mg/ml proteinase-K
(Roche) in Tris-EDTA (TE) buffer for 20 min at 37C, and endoge-
nous peroxidase activity blocked by incubating with 3% hydrogen
peroxide during 30 min at RT. Nonspeciﬁc binding sites were
blocked with 2.5% normal horse serum, sections were incubated
overnight with mouse monoclonal Col2 antibody (CIIC1; Develop-
mental studies hybridoma bank, Iowa City, IA). Sections were
incubated with anti-mouse Ig (ImmPRESS™ polymerized reporter
enzyme staining system, Vector Laboratories, CA) for 30 min, fol-
lowed by a short incubation with ImmPACT™ red peroxidase sub-
strate (Vector laboratories, CA).
Total GAG/DNA assay
The proteoglycan content of the aggregates was quantiﬁed using
methods described previously26, presented in detail in
Supplemental methods.
RNA isolation and real-time qPCR
Total RNA was isolated from cells using TRIzol® reagent (Invi-
trogen, Carlsbad, CA) according to the manufacturer's instructions.
Before RNA isolation, the aggregates were homogenized using
RNase-free disposable Pellet-Pestles® (Kimble-Chase, TN). The
sample was digested on-columnwith DNaseI and puriﬁed with the
RNeasy mini kit (Qiagen, Valencia, CA). One mg of total RNA wasFig. 1. Immunocytochemistry of hMSC stimulated with FGF2 during expansion phase and ge
the end of 14 days of expansion (Exp. e d0) and at early chondrogenic differentiation in aggr
control-expanded data at d0 and d3 independently (left panel) and against d0 for both group
rich medium. (C) FGFR1 and FGFR3 (n ¼ 3) gene expression proﬁles (assessed by qRT-PCR) e
(#): Statistical signiﬁcance (P < 0.0001) when data compared to control-expanded at d0. (&
Statistical signiﬁcances (P values) when Control and FGF2-expanded cells are compared at a
performed for all four donors (Sox9) and three donors (FGFRs) using triplicate samples.used for reverse transcription with SuperScript III (Invitrogen), and
10 ng of the resulting cDNA were quantiﬁed by qPCR using a Ste-
pOne Real-time thermocycler (Applied Biosystems). HPRT was
chosen to normalize the data; relative expression was calculated
according to the 2eDDCT method27.
Statistical analysis
Statistical analysis was conducted using GraphPad Prism soft-
ware (Version 5.0c for Mac OS X). Gene expression and GAG
quantiﬁcation assessment for normal distribution (ShapiroeWilk
and KolmogoroveSmirnov tests) was inconclusive based on small n
number. Visual analysis of the data shows no skewedness and
absence of outliers. Therefore, parametric test were used to calcu-
late statistical signiﬁcance, taking into account that with small
samples the non-parametric tests have little power to ﬁnd signiﬁ-
cant differences. Student's paired t-test (paired by donor) was used
to compare two groups and analysis of variance (ANOVA) with
Tukey's post hoc testing for multiple comparisons. Values are rep-
resented as means ± 95% conﬁdence intervals and signiﬁcance
assigned at P < 0.05.
Results
FGF2 effects during hMSC expansion and early chondrogenesis
We have previously shown that FGF2 treatment during expan-
sion enhances the proliferation and subsequent chondrogenicne expression during expansion and in vitro chondrogenesis: (A) Sox9 mRNA (n ¼ 4) at
egate cultures (Diff. e d3) with and without FGF2. Statistical comparisons made against
s (right panel). (B) Sox9 protein at the end of 14 days of expansion in control and FGF2-
valuated after 14 days of expansion (d0) and subsequent aggregate culture for 21 days.
): Statistical signiﬁcance (P < 0.0001) when data compared to FGF2-expanded at d0.
particular time-point are shown in the graph for clarity. Gene expression analysis was
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loss of differentiation capacity associated with cell passaging4,5. In
contrast, the addition of FGF2 later during differentiation in aggre-
gates has a negative effect on in vitro chondrogenesis12. This con-
trasting information suggests that the beneﬁcial effects of FGF2 on
hMSC-derived chondrogenic differentiation are limited to the pres-
ence of the ligand only during the expansion phase. We compared
the expression of Sox9 in control- and FGF2-expanded hMSC both at
the end of the expansion period (d0), and after 3 days in chondro-
genic aggregate cultures. As shown in Fig. 1, Sox9 mRNA and protein
are upregulated at the end of expansionwith FGF2 (d0) [Fig.1(A) and
(B)]. Later, after an initial exposure to chondrogenic medium for 3
days, Sox9 gene expression becomes comparable, due to a more
pronounced upregulation in control-expanded cells [Fig. 1(A)]. This
“catch up” effect can be explained by a “ceiling” effect on Sox9
expression. Examination of other related genes (Sox5, Sox6 and
Sox8) in similar conditions revealed an overall low expression during
this time. In conclusion, expanding hMSC in the presence of FGF2
shifts the activation of Sox9 earlier than in control-expanded cells.
Of the fourknownFGFreceptors (FGFRs), three (FGFR1, FGFR2 and
FGFR3) are expressed by hMSC12. We therefore looked for potential
altered expression of different FGFRs after expansion with FGF2 (in
comparison with control-expanded cells) and then during chondro-
genic induction in aggregate cultures. Consistent with that report,
FGFR1 was the most abundant at the end of expansion (both control
and FGF2-expanded cells),while FGFR2and FGFR3, althoughpresent,
were signiﬁcantly less expressed (Suppl. Fig. 1(A)). In contrast to
FGFR1and FGFR3,which experienced prominent changes at different
stages of chondrogenesis [Fig.1(C)], FGFR2 remained consistently low
and did not showany signiﬁcant difference in expression throughout
the examination period (Suppl. Fig. 1(B)). FGFR1 was downregulated
at the end of expansion (d0) in FGF2-rich medium, while the
expression of FGFR3, although exhibited a similar trend, did not reach
statistical difference [Fig. 1(C)]. Later during chondrogenic induction,0
1
2
3
d0 d5 d10 d15 d21
FG
FR
1
-f
ol
d
ex
pr
es
si
on
A)
C)
<0.0001
<0.0001
<0.0001
<0.0001
0
10
20
30
40
d0 d5 d10 d15 d21
FG
FR
3:
FG
FR
1
-R
at
io
Fig. 2. FGFR3, FGFR1 gene expression and FGFR3:FGFR1 ratio during hMSC chondrogenic
(n ¼ 3) were subjected to FGF9 or FGF18 stimulation from d0 to d21 of differentiation inducti
formation. Pellet cultures were harvested at day 5, 10, 15 and 21, and qRT-PCR performed to
with non-stimulated Control (black dots) and FGF2-expanded cells (white dots) are shown
obtained at every time point with FGF9 and FGF18 stimulation were compared with Control
values) shown in the graph for clarity. All other comparison were P > 0.1.FGFR1 remained low in FGF2-expanded cells, compared to day 0 and
to control-expanded cells. In contrast, FGFR3 was signiﬁcantly
upregulated exclusively during the ﬁrst 2 weeks of differentiation in
FGF2-expanded cells, returning to levels comparable to control-
expanded cells thereafter.
FGF9 and FGF18 effects on FGFRs expression during hMSC
chondrogenesis
Both FGF9 and FGF18 were weakly expressed at the end of
expansion. Then during aggregate culture their expression dropped
even more and remained low throughout the differentiation period
(Suppl. Fig. 1(C)). When exogenously administered to control-
expanded cells (starting at day 0 of aggregate culture), neither
ligand altered the expression of FGFR1 or FGFR3 during the entire
differentiation program (d0ed21), except from a negative effect
observed on FGFR3 at day 21 [Fig. 2(A) and (B)]. On the other hand,
when administered to FGF2-expanded cells, both ligands affected
FGFR1 and FGFR3 expression. During early differentiation (up to
day 10) they had no effect on FGFR1 expression while negative on
FGFR3 reducing its signiﬁcant upregulation obtained after expan-
sion with FGF2 (more pronounced with FGF9). Later during differ-
entiation (d15 onward), both factors similarly upregulated the two
receptors signiﬁcantly [Fig. 2(A) and (B)]. The resulting
FGFR3:FGFR1 ratio shows that both ligands counteract the high
ratio obtained after expansion with FGF2 throughout the entire
differentiation program, and in control-expanded cells during late
differentiation [Fig. 2(C)]. FGFR2 expression was not modiﬁed at
any time by either ligand (Suppl. Fig. 1(B)).
ECM deposition (anabolic effect)
As shown in Fig. 3, FGF9 and FGF18 showed a negative effect
when added to FGF2-expanded hMSC at the beginning of the0
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Fig. 3. Chondrogenic differentiation of FGF2-expanded hMSC in the presence of FGF9 or FGF18 (and variants) at different times of initial stimulation: FGF9, FGF18 or their variants
were administered starting at the beginning (d0), at day 7 (d7) and at day 14 (d14) of chondrogenic differentiation until day 21. (A) Histological assessment of representative pellets
showing the anabolic effect when stimulation starts at d14, and a negative effect when started earlier, speciﬁcally FGF9. Pellet shown in the insert (control) corresponds to black
dots shown on (B). (B) GAG/DNA quantiﬁcation and aggrecan gene expression analysis assessed by qRT-PCR, performed at day 21. Statistical signiﬁcance (#) was obtained for GAG/
DNA comparing all values to control pellet (black dots) with the following P values: bþ 9 (d0: 0.0010; d7: 0.0011; d14: 0.0017); bþ 9v1 (d14: 0.0001); bþ 18 (d14: 0.0021); bþ 18v3
(d14: 0.0008). All other comparisons were P > 0.2. For Aggrecan, signiﬁcance (#) gave the following P values: b þ 9 (d0: 0.0009; d7: 0.0021); b þ 9v1 (d14: 0.0011); b þ 18 (d0:
<0.0001; d7: <0.0001); b þ 18v3 (d14: 0.0007). All other comparisons were P > 0.2. N ¼ 4.
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both factors produced a clear anabolic effect when the stimulation
started later in culture (d14 to d21). This effect is again mediated by
FGFR3 as FGF9v1 and FGF18v3, mutated versions of FGF9 and 18,
which signal exclusively through FGFR3, increased the positive
anabolic effect evident as a higher toluidine blue staining
[Fig. 3(A)], GAG/DNA concentration and aggrecan mRNA upregu-
lation [Fig. 3(B)], and Col2 RNA and protein expression [Fig. 4(A)
and (B)]. To further study the speciﬁc role of FGFR3 and FGFR1 on
hMSC chondrogenesis, we added FGF9, FGF18 and their mutant
variants at day 14 until day 21, along with FGFR1 and FGFR3
neutralizing antibodies. As shown in Supplemental Fig. 2, this type
of neutralizing antibodies are able to penetrate and distribute ho-
mogeneously throughout the pellet after several days of adminis-
tration, thus showing accessibility of the antibodies to their targets
inside a structure with growing ECM. As expected, and similar to
the results shown in Figs. 3 and 4, both FGF9 and FGF18 had an
anabolic effect above the TGF-b effect, exacerbated even more with
the mutants, especially with FGF9v1. Blocking FGFR1 and FGFR3
had no effect and signiﬁcantly decreased, respectively, the anabolic
effect of both FGFs, suggesting a critical FGFR3-mediated positive
effect on ECM deposition. Interestingly, FGF9v1 has a greater
anabolic effect than the native FGF9 and FGF18 and the FGF18v3
variant as seen in the histology [Fig. 5(A)], the GAG/DNA assay and
the upregulation of Col2 and aggrecan mRNA [Fig. 5(B)], suggesting
a more potent effect of FGF9, when signaling exclusively through
FGFR3. In conclusion, FGF9 and FGF18 signaling via FGFR3 late
during chondrogenic differentiation have an anabolic effect above
TGF-b, with a greater response with FGF9.Both ligands did not have a signiﬁcant effect on cell proliferation
during monolayer culture (data not shown). Their effect was
restricted to pellet culture, showing that the anabolic effect was
due to ECM deposition and not an increase in the ECM-producing
cell number.
Delayed hypertrophy
The presence of FGFs at a later point during the differentiation
program presented another unanticipated signiﬁcant beneﬁt.
Compared with control-expanded cells at day 21, pellets madewith
FGF2-expanded hMSC exhibited an upregulation of the hypertro-
phy markers type 10 collagen (Col10), Runx2, matrix metal-
loproteinase 13 (MMP13) and vascular endothelial growth factor
(VEGF) [Fig. 6(A)], all suggestive of an earlier onset of terminal cell
differentiation. Interestingly, the addition of FGF9 or FGF18 (and
variants) during the last 2 weeks of an extended culture of FGF2-
expanded cells (d14 to d28) antagonized this upregulation in all
four genes [Fig. 6(B)]. Blocking FGFR3 prevents this antagonistic
effect in Runx2 expression (both FGF9 and FGF18), while in Col10,
MMP13 and VEGF it is only evident for FGF18. Blocking FGFR1, on
the other hand, does not have an impact on the effect of either FGF9
or FGF18. This suggests that signaling through FGFR3 is the main
responsible for the delayed hypertrophy phenotype downstream of
FGF18 signaling, and that FGF9may use alternate pathways, at least
to control certain hypertrophy genes. As a further conﬁrmation of
this effect, we tested both ligands with FGF2-expanded cells
directly stimulated to enhance terminal differentiation, in order to
assess their ability to antagonize conditions known to induce
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Fig. 4. Type 2 collagen Immunohistochemistry and gene expression of FGF2-expanded hMSC in the presence of FGF9 or FGF18 (and variants) at different times of initial stimulation:
Type 2 collagen presence in pellets subjected to same conditions as in Fig. 3, assessed at day 21 by immunohistochemistry (A) and qRT-PCR (B). Statistical signiﬁcance (#) was
obtained comparing all values to control pellet (black dots) with the following P values: b þ 9 (d0: <0.0001; d7: <0.0001); b þ 9v1 (d14: 0.0006); b þ 18 (d0: <0.0001; d7: <0.0001);
b þ 18v3 (d14: 0.0012). All other comparisons were P > 0.2. N ¼ 4.
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conditions, both FGF9 and FGF18 (and variants) were also able to
partially delay the appearance of induced hypertrophy-related
changes in cytomorphology (larger lacunae as previously re-
ported6,7), but more dramatically to reduce the activity of the
hypertrophy-speciﬁc marker ALP (Fig. 7). These effects are medi-
ated again mainly through FGFR3 signaling, as neutralizing FGFR3,
not FGFR1, reverted the ALP activity. In conclusion, FGF9 and FGF18,
signaling mainly via FGFR3, showed a delay in the presence of
hypertrophic changes during late chondrogenic differentiation of
hMSC.
Discussion
Tissue engineering for cartilage repair is focused on developing
strategies aimed at generating a durable tissuewith a stable hyaline
cartilage phenotype, a task that relies on the identiﬁcation and
manipulation of signaling pathways that promote chondrogenesis
and cartilage production. Several previous studies have focused on
the use of different growth factors to control hMSC-based chon-
drogenesis towards articular cartilage, some of themwith arguable
success, but still not efﬁciently bypassing the osteochondral fate of
hMSC6,28. The control of chondrogenesis starting with hMSC and
aiming for the correct and functional phenotype is certainly more
complex than can be accomplished by adding single chondrogenic
factors (i.e., TGF-b). This traditional approach fails to accomplish
those aims, mainly because the lack of integration of crucial tem-
poral aspects of the chondrogenic program regulation. We propose
that sequential addition of growth factors to cell culture medium is
a useful technique for stimulating efﬁcient chondrogenesis of hMSC
in vitro29e31.Members of the FGF superfamily of morphogens play a variety of
roles in chondrogenesis in vitro, as well as during development and
repair32. We and others have previously shown that FGF2, when
administered exclusively during hMSC expansion, enhances pro-
liferation, delays senescence, and primes the cells for a better
subsequent chondrogenic differentiation4,5,33. However, the precise
underlying mechanisms are not well understood.
We show that the presence of FGF2 during hMSC expansion
shifts earlier and upregulates the transcription factor Sox9, critical
in the early phases of chondrogenic differentiation of mesenchymal
precursors34,35. In addition, FGF2 modulates the expression of FGF
receptors, normally expressed in a distinct and stage-dependent
pattern and essential during chondrogenic differentiation. FGFR1,
critical during expansion36,37, but with a negative effect during
early chondrogenesis38, was signiﬁcantly downregulated
throughout the differentiation program. FGFR3, a known marker of
pre-cartilaginous cells39, that enhances matrix deposition22, and
that is poorly expressed in hMSC during expansion and early stages
of differentiation14,40, was signiﬁcantly upregulated at these early
stages. This resulting receptor proﬁle generated with FGF2 during
expansion can then be used during active differentiation to
enhance the positive effects of FGFR3 ligands such as FGF18 (and
FGF9 as proposed here), at times where they would normally not
signal efﬁciently. This is based on the fact that FGF18, signaling
speciﬁcally through FGFR3, exerts an anabolic effect during
chondrogenesis14e17.
Both FGF9 and FGF18 signal primarily through FGFR3, with
signaling through FGFR1 and FGFR2 reported as secondary mech-
anisms23. We found that these two ligands in turnmodulate FGFR3/
FGFR1 expression at all stages in a feedback loop manner (espe-
cially FGFR3). This negative feedback of FGF9/FGF18 is reﬂected on
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expression analysis of type 2 collagen and aggrecan, assessed by qRT-PCR performed at day 21. Statistical signiﬁcance (#) was obtained comparing all values to control pellet (black
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D. Correa et al. / Osteoarthritis and Cartilage 23 (2015) 443e453 449the FGFR3:FGFR1 ratio, which although is maintained high, it be-
comes closer to physiological levels when compared to human
articular cartilage (2.84 ± 0.9), and contrasted to other skeletal
tissues such as tendon: 0.71 ± 0.33; cruciate ligaments: 0.85 ± 0.34;
meniscus: 1.14 ± 0.46; muscle: 1.08 ± 0.08 and trabecular bone:
1.77 ± 0.04 (unpublished observations obtained from microarray
analysis of human samples). Interestingly, both receptors were high
at late stages of differentiation, where an anabolic response has
been documented22. Given the antagonistic signaling downstream
of these receptors, the FGFR3:FGFR1 ratio presented by Ellman et al.
and Vincent et al.14,21 becomes key to the biological outcome of
FGFs, and could be used to evaluate FGF9/FGF18 effects on hMSC
chondrogenesis.
As the chondrogenic program of hMSC progresses, we found
that FGF18 and FGF9, signaling through FGFR3, have anabolic
effects on ECM production. Remarkably, we found a greater effect
with FGF9 than with FGF18, allowing us to speculate a potential
entry of FGF9 into clinical trials for the treatment of cartilage
injuries, as FGF18 is currently under clinical investigation (www.
clinicaltrials.gov NCT01066871, NCT01689337, NCT01033994,
NCT01919164, NCT00911469). The addition of FGF9 only at earlystages of differentiation has been shown to have no signiﬁcant
effect on GAG deposition, but a prolonged exposure can cause a
signiﬁcant decrease in GAG deposition12. Similarly, we found that
the addition of FGF9 or FGF18 as early as day 0 and day 7 and
until day 21 partially inhibits ECM deposition. In contrast, their
addition at a later time point (from day 14 until day 21) stimu-
lates an anabolic effect. These observations underline the tem-
poral control of FGF supplementation, which is critical for
successful hMSC-derived chondrogenesis. Furthermore, FGF9 and
FGF18 mutant variants, which signal exclusively through FGFR3
had the greatest positive effects, unmasking the FGFR3-
dependent effects and emphasizing the importance of avoiding
downstream signaling antagonism. These differential effects of
FGF signaling reﬂect the dependency on the differentiation state
of the cells, the FGFRs repertoire they express at determined time
points during the program and the presence of speciﬁc growth
factors. This dynamic balance of FGFR expression is also impor-
tant during disease. Yan and colleagues showed a signiﬁcant
reduction in FGFR3 expression in human OA cartilage compared
to normal post-mortem samples38, implying that exogenous
administration of FGF9/FGF18 would have a suboptimum effect
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approach may be based on strategies that augment FGFR3 levels
within diseased tissues in order to potentiate the beneﬁcial ef-
fects of these FGF family members once administered41. Alter-
natively, more potent and/or highly selective ligands may well
prove superior for cartilage repair and as disease modifying
agents in OA.
An unanticipated consequence of expanding hMSC with FGF2 is
the early appearance of hypertrophy-related features. This phe-
nomenon can be explained by a shift in the entire differentiation
program, so the cells prematurely experience these terminally
differentiation changes as part of their intrinsic ability to enter and
ﬁnish an endochondral ossiﬁcation program. In the pre-
hypertrophic and hypertrophic zones of developing cartilage,
both FGF18 and FGF9 interact with FGFR1 to promote vascular in-
vasion and further terminal differentiation22. Our results pointing
towards an inhibitory role of FGFR3 signaling to hypertrophic ter-
minal differentiation suggest that the high FGFR3:FGFR1 ratio ob-
tained with FGF9/FGF18 would be favorable to avoid hypertrophic
differentiation. On the other hand, data regarding the effect of TGF-
b on hypertrophic differentiation are conﬂicting. Previous obser-
vations from our group show that hypertrophic differentiation of
hMSC following bone morphogenetic protein 2 (BMP-2) adminis-
tration could be delayed by co-treatment with TGF-b42. Contrary,
other groups have reported that TGF-b can secondarily induce hy-
pertrophy in in vitro differentiating hMSC9, as well as in vivo after
implantation of pre-differentiated cartilage pellets in severe com-
bined immunodeﬁciency (SCID) mice8. Regardless of the contro-
versy, our results suggest that co-treatment with FGF9 and FGF18
may become necessary to modulate the hypertrophic phenotypic
conversion.
In conclusion, we found that a sequential exposure of hMSC to
members of the FGF family of morphogens has a signiﬁcant impact
on three main challenges during in vitro chondrogenesis, that inturn have critical roles during the generation of engineered carti-
lage implants (Fig. 8): (1) cell expansion (FGF2): key to maximize
hMSC expansion potential, as large numbers of cells are required
for tissue engineering; (2) chondrogenic differentiation (FGF9/
FGF18): critical determinant of the long-term durability and clinical
success of engineered cartilage is the amount and composition of
the secreted ECM, and (3) hypertrophic differentiation (FGF9/
FGF18): as osteochondral progenitors, hMSC appear to follow an
intrinsic differentiation program that involves progression to a
terminal hypertrophic differentiation, an undesirable cellular
phenotype when attempting to generate hyaline articular cartilage.
Our results collectively constitute the basis for a re-evaluated
proposition, one in which a factor not only has a speciﬁc effect on
the cells but also establishes the ideal conditions for the action of
another one sequentially delivered, that serves to amplify its effect.
These data emphasize the importance of timing of exposure to the
growth factors particularly due to the tight spatio-temporal control
of these factors and their speciﬁc receptors at different stages of
development. Understanding these temporal changes is therefore
critical in determining the ligandereceptor interactions that are
primarily responsible for the control of the ultimate cellular
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